Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration…
Read More
Publications Archive for ‘Fragile X’
Tweets
Autifony CEO Charles Large will be speaking at the a webinar ‘Fragile X syndrome – in pursuit of a cure’ World Frag… https://t.co/DPw8f5LPMN
We are currently recruiting for a Senior Electrophysiologist who will be based in Padova Italy, please apply by sen… https://t.co/QL4GySZbKH
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
© Copyright 2021 Autifony Therapeutics
